Antitumor necrosis factor (TNF) alpha therapy is commonly used to treat severe rheumatoid arthritis (RA) and has been proven efficacious in psoriatic arthritis, a condition which involves the combined occurrence of psoriasis and inflammatory arthritis. However, the findings of a recent observational cohort study in patients from the British Society for Rheumatology Biologics Register (BSRBR) suggest that anti-TNF-alpha therapy in patients with RA may be associated with an elevated risk of developing psoriasis compared to treatment with traditional disease-modifying antirheumatic drugs (DMARDs). Patients who had received anti-TNF-alpha therapy (n = 9,826) and a comparison cohort treated with DMARDs (n = 2,880 patients) participated in the study. Anti-TNF-alpha therapy included administration of the ...